Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of approximately 0.36 billion yuan in 2025, reflecting a year-on-year decline of about 59.69% [1][5]. - The company has faced significant pressure on profit margins due to rising raw material costs, particularly for whey protein products, but has managed to improve operational efficiency and achieve a quarter-on-quarter profit turnaround in Q4 [1]. - The company has developed a patented nutritional formula "CPTpro," which enhances protein absorption rates from 91% to 98% and increases muscle synthesis rates by 1.9 times, contributing to its competitive edge in the market [2]. Financial Projections - Revenue projections for 2025 are set at 1.153 billion yuan, with expected growth rates of 10.9% in 2025, 21.4% in 2026, and 25.1% in 2027 [3]. - The net profit forecast for 2025 is 0.36 billion yuan, with subsequent projections of 0.64 billion yuan in 2026 and 1.06 billion yuan in 2027, indicating a recovery trend after the anticipated decline in 2025 [3]. - The company's price-to-earnings (P/E) ratios are projected to be 53.9 for 2025, 30.6 for 2026, and 18.3 for 2027, reflecting a decreasing trend as earnings improve [3].
康比特（920429）：2025年业绩预告点评：产品结构持续优化，带动四季度利润回暖